Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA

被引：0
|
作者：
Grohe, C. [1 ]
Herbst, R. S. [2 ,3 ]
Tsuboi, M. [4 ]
John, T. [5 ]
Majem, M. [6 ]
Goldman, J. W. [7 ]
Kim, S. -W. [8 ]
Marmol, D. [9 ]
Rukazenkov, Y. [10 ]
Wu, Y. -L. [11 ]
Engel-Riedel, W. [12 ]
机构：
[1] Evangel Lungenklin Berlin Buch, Klin Pneumol, Berlin, Germany
[2] Yale Sch Med, Med Oncol, New Haven, CT USA
[3] Yale Canc Ctr, New Haven, CT USA
[4] Natl Canc Ctr Hosp East, Dept Thorac Surg & Oncol, Chiba, Japan
[5] Austin Hlth, Dept Med Oncol, Heidelberg, Vic, Australia
[6] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[7] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[8] Asan Med Ctr, Dept Oncol, Seoul, South Korea
[9] AstraZeneca, Late Oncol Stat, Cambridge, England
[10] AstraZeneca, Oncol Res & Dev, Cambridge, England
[11] South China Univ Technol, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci,Sch Med, Guangzhou, Peoples R China
[12] Klinikum Stadt Koln gGmbH, Cologne, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
166
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [21] Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB-IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection
    Tsuboi, M.
    Herbst, R. S.
    John, T.
    Grohe, C.
    Majem, M.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Miziara, J. E. A.
    Novello, S.
    Urban, D.
    Akewanlop, C.
    Ozturk, A.
    Quang, B. V.
    Kowalski, D.
    Marmol, D.
    Marotti, M.
    Laus, G.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2019, 30 : 589 - 589
  • [22] Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR plus NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
    Zhang, Shannon S.
    Ou, Sai-Hong Ignatius
    LUNG CANCER-TARGETS AND THERAPY, 2022, 13 : 23 - 31
  • [23] Biomarker testing and adjuvant osimertinib use in patients with resectable EGFR-mutated stage IB-IIIA NSCLC: Physician practices, therapy choice, and barriers among US oncologists
    Aggarwal, Puja
    Savill, Kristin M. Zimmerman
    Jeune-Smith, Yolaine
    Jennings-Zhang, Luke
    Bone, Robert
    Kelly, Ronan Joseph
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
    Chen, Ping
    Yang, Qing
    Li, Yinfeng
    Jing, Xiaomei
    Chen, Jing
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
    Brazel, Danielle
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2022, 13 : 47 - 52
  • [26] ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection
    Wu, Yi-Long
    Herbst, Roy S.
    Mann, Helen
    Rukazenkov, Yuri
    Marotti, Marcelo
    Tsuboi, Masahiro
    CLINICAL LUNG CANCER, 2018, 19 (04) : E533 - E536
  • [27] IMpower010: Characterization of Stage IB-IIIA NSCLC Patients by Type and Extent of Therapy Prior to Adjuvant Atezolizumab
    Altorki, N.
    Felip, E.
    Zhou, C.
    Vallieres, E.
    Moiseyenko, V.
    Smolin, A.
    Rittmeyer, A.
    Vereshchako, R.
    Perol, M.
    Schutte, W.
    Fang, J.
    Tao, M.
    Teixeira, E.
    Kim, Y.
    Gitlitz, B.
    Bennett, E.
    Mcnally, V.
    Wu, F.
    Deng, Y.
    Wakelee, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S845 - S846
  • [28] Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
    Herbst, Roy S.
    Wu, Yi-Long
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Wang, Jie
    Kato, Terufumi
    Goldman, Jonathan W.
    Laktionov, Konstantin
    Kim, Sang-We
    Yu, Chong-Jen
    Vu, Huu Vinh
    Lu, Shun
    Lee, Kye Young
    Mukhametshina, Guzel
    Akewanlop, Charuwan
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Urban, Damien
    Huang, Xiangning
    Bolanos, Ana
    Stachowiak, Marta
    Tsuboi, Masahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (10) : 1830 - +
  • [29] Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC
    Schmid, S.
    Garcia, M.
    Hueniken, K.
    Balaratnam, K.
    Patel, D.
    Zhan, L.
    Brown, M. C.
    Sacher, A.
    Bradbury, P.
    Leighl, N.
    Shepherd, F. A.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S945 - S945
  • [30] ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection
    Herbst, R.
    Wu, Y.
    Mann, H.
    Rukazenkov, Y.
    Marotti, M.
    Tsuboi, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2399 - S2400
12345